ENANTA PHARMACEUTICALS INC - ENTA
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Mar 26, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Deep Track Capital, LP | 6.78% | 1,956,867 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | Deep Track Biotechnology Master Fund, Ltd. | 6.78% | 1,956,867 | View |
| Feb 13, 2026 | SCHEDULE 13G/A | David Kroin | 6.78% | 1,956,867 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Farallon Capital Partners, L.P. | 1.8% | 531,119 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Farallon Capital Institutional Partners, L.P. | 2.1% | 595,851 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Farallon Capital Institutional Partners II, L.P. | 0.5% | 150,355 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Farallon Capital Institutional Partners III, L.P. | 0.3% | 84,528 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Four Crossings Institutional Partners V, L.P. | 0.4% | 108,002 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Farallon Capital Offshore Investors II, L.P. | 3.8% | 1,110,733 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Farallon Capital (AM) Investors, L.P. | 0.2% | 60,191 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Farallon Capital F5 Master I, L.P. | 0.6% | 176,083 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Farallon Partners, L.L.C. | 9.1% | 2,640,779 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Farallon Institutional (GP) V, L.L.C. | 0.4% | 108,002 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Farallon F5 (GP), L.L.C. | 0.6% | 176,083 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Dapice Joshua J. | 9.8% | 2,816,862 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Dreyfuss, Philip D. | 9.8% | 2,816,862 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Dunn Hannah E. | 9.8% | 2,816,862 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Fried, Richard B | 0.0% | 0 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Gehani, Varun N. | 9.8% | 2,816,862 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Giauque, Nicolas | 9.8% | 2,816,862 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Husen, Avner A. | 9.8% | 2,816,862 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Kim, David T. | 9.8% | 2,816,862 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Linn, Michael G. | 9.8% | 2,816,862 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Luo Patrick (Cheng) | 9.8% | 2,816,862 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Patel, Rajiv A. | 0.0% | 0 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Roberts, Jr., Thomas G. | 9.8% | 2,816,862 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Saito Edric C. | 9.8% | 2,816,862 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Seybold, William | 0.0% | 0 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Short Daniel S. | 9.8% | 2,816,862 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Spokes, Andrew J. M. | 9.8% | 2,816,862 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Warren, John R. | 9.8% | 2,816,862 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Wehrly, Mark C. | 9.8% | 2,816,862 | View |
| Jan 20, 2026 | SCHEDULE 13G/A | Integrated Core Strategies (US) LLC | 2.3% | 665,953 | View |
| Jan 20, 2026 | SCHEDULE 13G/A | Millennium Management LLC | 2.3% | 670,428 | View |
| Jan 20, 2026 | SCHEDULE 13G/A | Millennium Group Management LLC | 2.3% | 670,428 | View |
| Jan 20, 2026 | SCHEDULE 13G/A | Israel A. Englander | 2.3% | 670,428 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Integrated Core Strategies (US) LLC | 4.0% | 1,112,864 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Millennium Management LLC | 4.1% | 1,138,484 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Millennium Group Management LLC | 4.1% | 1,138,484 | View |
| Nov 13, 2025 | SCHEDULE 13G/A | Israel A. Englander | 4.1% | 1,138,484 | View |
| Nov 07, 2025 | SCHEDULE 13G | JANUS HENDERSON GROUP PLC | 12.1% | 3,494,068 | View |
| Nov 07, 2025 | SCHEDULE 13G | Janus Henderson Biotech Innovation Master Fund Ltd | 10.6% | 2,959,525 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.